Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 5/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415465 | 0.90 | ALDH3A1 (0.50) | HTR6ALDH3A1NOD1CXCL8NOD2 | |
| SCHEMBL26234322 | 0.79 | KDM4E (0.35) | LMNAALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL18687118 | 0.78 | ALDH3A1 (0.46) | HTR6ALDH3A1NOD1CXCL8NOD2 | |
| SCHEMBL12800988 | 0.77 | MAPK1 (0.37) | LMNAALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL12801036 | 0.77 | KDM4E (0.47) | LMNAALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL21346769 | 0.77 | KDM4E (0.40) | LMNAGAAALDH1A1HPGDHTT | |
| SCHEMBL12800861 | 0.77 | GPR3 (0.42) | LMNAALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL23652553 | 0.76 | ALDH3A1 (0.43) | HTR6ALDH3A1NOD1CXCL8NOD2 | |
| SCHEMBL23118271 | 0.75 | ALDH1A1 (0.44) | HTR6ALDH3A1NOD1CXCL8NOD2 | |
| SCHEMBL18083415 | 0.75 | KDM4E (0.43) | LMNAALDH1A1HPGDHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10862051-B2 | Benzimidazo[1,2-a]benzimidazole derivatives for electronic applications | UDC IRELAND LIMITED (IE) | 2020-12-08 | — | — | US | disclosed |
| US-20190181355-A1 | Benzimidazo[1,2-a]Benzimidazole Derivatives for Electronic Applications | UDC IRELAND LTD (IE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190181355-A1 | Benzimidazo[1,2-a]Benzimidazole Derivatives for Electronic Applications | PAICS, EIF4A1, ECI1 | HTR6 3858/4885ALDH3A1 980/4885NOD1 2274/4885 |
| US-10862051-B2 | Benzimidazo[1,2-a]benzimidazole derivatives for electronic applications | PAICS, EIF4A1, ECI1 | HTR6 3858/4885ALDH3A1 980/4885NOD1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.